Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Infectious Diseases: Antibodies and Vaccines
share announcement

Infectious Diseases: Antibodies and Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 902

Special Issue Editors

Dr. Huibin Lv

E-Mail Website
Guest Editor
Department of Biochemistry, University of Illinois at Urbana Champaign, Urbana, IL 61801, USA
Interests: Influenza vaccine; antibody screening; antibody waning
Dr. Yupeng Feng

E-Mail Website
Guest Editor
Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA
Interests: system biology; systems vaccinology; antibody screening

Special Issue Information

Dear Colleagues,

In the ongoing battle against human infectious diseases, antibodies and vaccines stand as powerful weapons, providing both preventive and therapeutic functions. This Special Issue serves as a comprehensive exploration of the latest advancements and insights in the field of immunology, focusing on the roles of antibodies and vaccines in combating infectious pathogens.

This Special Issue presents a diverse array of research, ranging from fundamental discoveries in antibody biology to cutting-edge developments in vaccine design and delivery. Through a multidisciplinary lens, our topic delves into various aspects of immunity, including the generation of neutralizing antibodies, the mechanisms of vaccine-induced protection, and the challenges posed by emerging infectious threats.

Key topics addressed in this Special Issue are as follows:

  • Novel vaccine platforms and adjuvants for enhancing immune responses;
  • Harnessing monoclonal antibodies for therapeutic intervention against infectious agents;
  • Immune correlates of protection and their implications for vaccine efficacy;
  • Strategies for enhancing vaccine uptake.

Kind regards,

Dr. Huibin Lv
Dr. Yupeng Feng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neutralizing antibody
  • infectious disease
  • cross-reactive
  • epitope
  • vaccine design

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 2011 KiB  
Review
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2
by Meng Yuan and Ian A. Wilson
Vaccines 2024, 12(5), 467; https://doi.org/10.3390/vaccines12050467 - 27 Apr 2024
Viewed by 490
Abstract
Public antibody responses have been found against many infectious agents. Structural convergence of public antibodies is usually determined by immunoglobulin V genes. Recently, a human antibody public class against SARS-CoV-2 was reported, where the D gene (IGHD3-22) encodes a common YYDxxG motif in [...] Read more.
Public antibody responses have been found against many infectious agents. Structural convergence of public antibodies is usually determined by immunoglobulin V genes. Recently, a human antibody public class against SARS-CoV-2 was reported, where the D gene (IGHD3-22) encodes a common YYDxxG motif in heavy-chain complementarity-determining region 3 (CDR H3), which determines specificity for the receptor-binding domain (RBD). In this review, we discuss the isolation, structural characterization, and genetic analyses of this class of antibodies, which have been isolated from various cohorts of COVID-19 convalescents and vaccinees. All eleven YYDxxG antibodies with available structures target the SARS-CoV-2 RBD in a similar binding mode, where the CDR H3 dominates the interaction with antigen. The antibodies target a conserved site on the RBD that does not overlap with the receptor-binding site, but their particular angle of approach results in direct steric hindrance to receptor binding, which enables both neutralization potency and breadth. We also review the properties of CDR H3-dominant antibodies that target other human viruses. Overall, unlike most public antibodies, which are identified by their V gene usage, this newly discovered public class of YYDxxG antibodies is dominated by a D-gene-encoded motif and uncovers further opportunities for germline-targeting vaccine design. Full article
(This article belongs to the Special Issue Infectious Diseases: Antibodies and Vaccines)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop